摘要
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 是 COVID-19 传染病的病原体,通过呼吸道传播并已达到全球大流行的严重程度。随着疾病的恶化,COVID-19 的症状可能从轻微(发烧、干咳、呼吸急促)到严重的肺炎样呼吸道症状不等。与 SARS-CoV 不同,SARSCoV-2 对 ACE-2 受体具有更高的结合亲和力,这意味着其在人与人之间的传播率更高。尽管 ACE-2 在对各种器官表现出保护作用的肾素血管紧张素-醛固酮系统 (RAAS) 调节中具有重要意义,但它在 COVID-19 疾病的发病机制中发挥着重要作用。在感染 SARS-CoV-2 的患者中发现了对 ACE-2 肽酶活性的病毒干扰,导致促炎反应、高血压和多器官损伤。血管紧张素转换酶 2 受限于多种器官系统,但肺上皮细胞表面的 ACE-2 受体受到很大影响,这导致肺组织学的病理改变,可能进展为呼吸衰竭。病毒趋向性主要通过附着在宿主细胞中的血管紧张素转换酶-2受体上发生;因此,靶向 ACE-2 表达的药物可能会成为未来对抗 COVID-19 感染的治疗策略。重新利用药物的创新方法已显示出遏制日益严重的流行病的暂时有效性。本文主要关注在 COVID 感染期间表达的 ACE-2 受体的重要性以及现有药物疗法的再利用策略。
关键词: SARS-CoV-2、ACE-2 受体、严重急性呼吸综合征 (SARS)、抗病毒治疗、RAAS、COVID-19。
Current Molecular Medicine
Title:The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise
Volume: 21 Issue: 10
关键词: SARS-CoV-2、ACE-2 受体、严重急性呼吸综合征 (SARS)、抗病毒治疗、RAAS、COVID-19。
摘要: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent for the COVID-19 infectious disease that spreads via the respiratory route and has reached a drastic level of a global pandemic. Symptoms of COVID-19 may vary from mild (fever, dry cough, shortness of breath) to severe pneumonia-like respiratory symptoms as exacerbation of disease occurs. Unlike SARS-CoV, the SARSCoV- 2 has a higher binding affinity to ACE-2 receptors, which signifies its higher transmission rate from person to person. Even though ACE-2 is significant in the reninangiotensin- aldosterone system (RAAS) regulation that exhibits protection to various organs, it plays a significant role in COVID-19 disease pathogenesis. Viral interferences with the ACE-2 peptidase activity are found in SARS-CoV-2 infected patients leading to pro-inflammatory responses, hypertension and multi-organ damage. Angiotensinconverting enzyme-2 is constrained to a variety of organ systems, but surface ACE-2 receptors on lung epithelia are largely affected, which lead to pathological alterations in lung histology which may progress to respiratory failure. The viral tropism mainly occurs by the attachment to the angiotensin-converting enzymes-2 receptors in the host cell; thus drugs targeting ACE-2 expressions may arise as the future therapeutic strategy to combat COVID-19 infections. The innovative approach of repurposing drugs has shown temporary effectiveness to curb the rising pandemic. This article mainly focuses on the prominence of ACE-2 receptors which are expressed during the COVID infections and the repurposing strategy of available drug therapies.
Export Options
About this article
Cite this article as:
The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise, Current Molecular Medicine 2021; 21 (10) . https://dx.doi.org/10.2174/1573405617666210204212024
DOI https://dx.doi.org/10.2174/1573405617666210204212024 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease
Current Alzheimer Research Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research Effects of Carnosine Plus Vitamin E and Betaine Treatments on Oxidative Stress in Some Tissues of Aged Rats
Current Aging Science Catecholaminergic Strategies for the Treatment of Major Depression
Current Drug Targets Iodine in Mammary and Prostate Pathologies
Current Chemical Biology Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Recent Advances in Adenovirus-mediated Gene Therapy for Cerebral Ischemia
Current Gene Therapy Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Current Pharmaceutical Biotechnology Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Non Steroidal Anti-Inflammatory and Anti-Allergy Agents
Current Medicinal Chemistry A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19)
Infectious Disorders - Drug Targets TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Pro-inflammatory Cytokines in Animal and Human Gestation
Current Pharmaceutical Design Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology Development of a Suitable Dissolution Method for the Combined Tablet Formulation of Atorvastatin and Ezetimibe by RP-LC Method
Current Drug Delivery Statins in Stroke Prevention: Present and Future
Current Pharmaceutical Design